Anson Funds Management LP Has $9.71 Million Position in SELLAS Life Sciences Group, Inc. $SLS

Key Points

• Anson Funds Management boosted its position in SELLAS by 2,093.8% in Q3 and now owns 6,032,938 shares (about 4.82% of the company) valued at approximately $9.71 million, making SLS its 20th largest holding.
• SELLAS shares opened at $5.37 and were trading up ~6.8%; the stock has a market cap of $764.9M, a 1‑year range of $0.95–$6.14, a 50‑day MA of $4.35 and a 200‑day MA of $2.79, indicating recent upward momentum.
• Analyst sentiment is mixed—Weiss Ratings reaffirmed a "sell (d-)", there is one Buy and one Sell for an average "Hold" rating and a consensus target of $7.00—while the company remains a clinical‑stage biotech developing the WT1‑targeting vaccine galinpepimut‑S.

Anson Funds Management LP raised its holdings in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) by 2,093.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,032,938 shares of the company's stock after buying an additional 5,757,938 shares during the quarter. SELLAS Life Sciences Group accounts for approximately 0.8% of Anson Funds Management LP's holdings, making the stock its 20th biggest holding. Anson Funds Management LP owned approximately 4.82% of SELLAS Life Sciences Group worth $9,713,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. ProShare Advisors LLC bought a new position in shares of SELLAS Life Sciences Group during the 2nd quarter worth about $43,000. Geode Capital Management LLC increased its stake in SELLAS Life Sciences Group by 168.2% in the second quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company's stock valued at $4,819,000 after acquiring an additional 1,379,988 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new stake in SELLAS Life Sciences Group in the second quarter valued at about $51,000. Intech Investment Management LLC acquired a new position in SELLAS Life Sciences Group in the second quarter worth about $101,000. Finally, JPMorgan Chase & Co. acquired a new position in SELLAS Life Sciences Group in the second quarter worth about $136,000. Institutional investors and hedge funds own 17.38% of the company's stock.

SELLAS Life Sciences Group Trading Up 6.8%

NASDAQ:SLS opened at $5.37 on Friday. The stock has a market capitalization of $764.90 million, a P/E ratio of -19.18 and a beta of 2.18. SELLAS Life Sciences Group, Inc. has a 1 year low of $0.95 and a 1 year high of $6.14. The firm has a 50 day moving average of $4.35 and a 200-day moving average of $2.79.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $7.00.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

Want to see what other hedge funds are holding SLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.